Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma

Clinical Transplantation

Volumn 26, Issue 4, 2012, Pages

  Park, Sang Jae ^a   Freise, Chris E ^b   Hirose, Ryutaro ^b   Kerlan, Robert K ^b   Yao, Francis Y ^b   Roberts, John P ^b   Vagefi, Parsia A ^c  

^a National Cancer Center   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Hepatocellular carcinoma; Liver transplantation; Loco regional therapy; MELD; MELD exception points; Waitlist dropout

Indexed keywords

ALCOHOL;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CHEMOEMBOLIZATION; DECOMPENSATED LIVER CIRRHOSIS; FEMALE; HEALTH CARE ACCESS; HOSPITAL ADMISSION; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MELD SCORE; PERCUTANEOUS ETHANOL INJECTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RISK FACTOR; SCORING SYSTEM;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE RATIONING; HUMANS; LIVER FAILURE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT DROPOUTS; PATIENT SELECTION; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; WAITING LISTS;

EID: 84864954136     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2012.01668.x     Document Type: Article

References (24)

1. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996: 334: 693.
2. Malinchoc M, Kamath PS, Gordon FD et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000: 31: 864.
3. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end stage liver disease. Hepatology 2001: 33: 464.
4. Yao FY, Xiao L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007: 7: 2587.
5. Yao FY, Bass N, Ascher N et al. Liver transplantation for hepatocellular carcinoma: lessens from the first year under the model of end-stage liver disease (MELD) organ allocation policy. Liver Transpl 2004: 10: 621.
6. Freeman RB, Edwards EB, Harper AM. Waiting list removal rates among patients with chronic and malignant liver disease. Am J Transplant 2006: 6: 1416.
7. Yao FY, Bass NM, Nikolai B et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003: 7: 684.
8. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999: 30: 1434.
9. Maddala YK, Stadheim L, Andrews JC et al. Drop-out rats of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 2004: 10: 449.
10. Fisher RA, Maluf D, Cotterell AH et al. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intension-to-treat and dropout from liver transplant waiting list. Clin Transplant 2004: 18: 502.
11. Lu DSK, Yu NC, Raman SS et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005: 41: 1130.
12. Cillo U, Vitale A, Grigoletto R et al. Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria. Am J Transplant 2007: 7: 972.
13. United Network of Organ Sharing. Policy 3.6. Available via the internet at www.unos.org.
14. Sherman M, Klein A. A AASLD single-topic research conference on HCC. Conference Proceeding. Hepatology 2004: 40: 1465.
15. Yao FY, Hirose R, LaBerge JM et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 2005: 11: 1505.
16. Edmondson H, Steiner P. Primary carcinoma of the liver: a study of 100 cases among 48, 900 necropsies. Cancer 1954: 1: 462.
17. Freeman FB, Harper A, Edwards EB et al. The MELD/PELD system and hepatocellular carcinoma. Liver Trasnpl 2003: 9: C31.
18. Graziadei IW, Sandmueller H, Waldenberger P et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003: 9: 557.
19. Chapman WC. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008: 248: 617.
20. Lesurtel M, Müllhaupt B, Pestalozzi BC et al. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 2006: 6: 2644.
21. Otto G, Herber S, Heise M et al. Response for transarterial chemo embolization as a biologic selection criteria for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006: 12: 1260.
22. Millonig G, Graziadei IW, Freund MC et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007: 13: 272.
23. Washburn K, Edwards E, Harper A et al. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 2010: 10: 1643.
24. Berg CL, Merion RM, Shearon TH et al. Liver transplant recipient survival benefit with living donation in the MELD allocation era. Hepatology 2011: 54: 1313.